Delcath Systems, Inc. (NASDAQ:DCTH) Shares Purchased by Barclays PLC

Barclays PLC boosted its position in Delcath Systems, Inc. (NASDAQ:DCTH) by 466.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 65,006 shares of the company’s stock after purchasing an additional 53,527 shares during the quarter. Barclays PLC owned about 0.20% of Delcath Systems worth $782,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Kennedy Capital Management LLC lifted its stake in shares of Delcath Systems by 89.6% in the fourth quarter. Kennedy Capital Management LLC now owns 258,782 shares of the company’s stock worth $3,116,000 after buying an additional 122,318 shares in the last quarter. ADAR1 Capital Management LLC lifted its stake in Delcath Systems by 381.1% in the 4th quarter. ADAR1 Capital Management LLC now owns 149,385 shares of the company’s stock worth $1,799,000 after purchasing an additional 118,333 shares in the last quarter. Aristides Capital LLC acquired a new position in shares of Delcath Systems during the 4th quarter worth approximately $325,000. Riverwater Partners LLC grew its position in shares of Delcath Systems by 46.2% in the fourth quarter. Riverwater Partners LLC now owns 27,229 shares of the company’s stock valued at $328,000 after purchasing an additional 8,601 shares in the last quarter. Finally, ExodusPoint Capital Management LP increased its holdings in shares of Delcath Systems by 32.2% in the fourth quarter. ExodusPoint Capital Management LP now owns 51,697 shares of the company’s stock valued at $622,000 after purchasing an additional 12,604 shares during the last quarter. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Trading Down 2.3 %

Shares of DCTH opened at $11.72 on Wednesday. The company’s 50-day moving average price is $12.32 and its 200 day moving average price is $12.53. Delcath Systems, Inc. has a 12-month low of $5.30 and a 12-month high of $16.97. The firm has a market cap of $391.83 million, a P/E ratio of -8.68 and a beta of 0.72.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The company had revenue of $15.10 million during the quarter, compared to analyst estimates of $14.96 million. During the same quarter in the prior year, the company posted ($0.48) earnings per share. Equities research analysts forecast that Delcath Systems, Inc. will post -0.79 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the company. HC Wainwright upped their target price on Delcath Systems from $22.00 to $24.00 and gave the company a “buy” rating in a report on Friday, March 7th. Craig Hallum raised their price objective on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.75.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.